Safety of virus inactivated antithrombin III concentrate antithrombin III immuno (AT III).
In a prospective clinical trial the risk of infection after application of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III) was investigated in patients undergoing cardiovascular surgery. The study was conducted according to the recommendations of the International Committee on Thrombosis and Hemostasis (ICTH), with the exception that most patients required additional blood products as well as AT III. Twenty-seven patients were eligible to test for the risk of acquiring hepatitis B. Twenty-six patients could be evaluated in terms of hepatitis NANB transmission considering ALT-levels whereas 20 patients could be tested for anti-HCV one year after surgery. Samples from 78 patients could be monitored for anti-HIV-1. None of these patients showed any signs of infection. AT III IMMUNO seems to be an antithrombin III concentrate with low or absent infectivity.
Preiss
D U
DU
Department of Anesthesia, Benedikt Kreutz Rehabilitation Center, Bad Krozingen, FRG.
Abdullah
D
D
Eberspächer
B
B
Wilhelm
K
K
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission*; D000990:Antithrombin III / Q000008:administration & dosage*; D001782:Blood Donors; D006348:Cardiac Surgical Procedures; D006525:Hepatitis, Viral, Human / Q000635:transmission*; D006801:Humans; D011446:Prospective Studies; D012307:Risk Factors; D065227:Transfusion Reaction
D000990:Antithrombin III